{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:31:23Z","timestamp":1789140683308,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the clinical outcomes of the switch to faricimab in a treat-and-extend (T&amp;E) regimen patients with neovascular age-related macular degeneration (nAMD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective cohort study included consecutive patients with nAMD who had previously been treated with anti-VEGF agents in a T&amp;E regimen, with treatment intervals (TI) that could not be extended beyond 12 weeks, and a minimum follow-up of 24 weeks. These patients were switched to faricimab therapy in a T&amp;E regimen for at least 6 months. The primary endpoint was the TI between intravitreal injections (IVIs), and the secondary endpoint was the mean change in best-corrected visual acuity (BCVA) from baseline to the last follow-up visit (LFUV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 225 eyes from 188 patients were included, with a mean age of 79.6\u2009\u00b1\u20097.4 years. Previous anti-VEGF treatments included ranibizumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200934), aflibercept (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009144), brolucizumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096), and bevacizumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200941). TI1 (5.9\u2009\u00b1\u20092.0 weeks) matched the prior treatment interval. Significant increases in treatment intervals were observed at subsequent time points (TI2: 8.2\u2009\u00b1\u20093.2 weeks, TI3: 10.1\u2009\u00b1\u20093.9 weeks, TI4: 10.7\u2009\u00b1\u20094.3 weeks, TI5: 9.9\u2009\u00b1\u20094.0 weeks, and TI6: 8.5\u2009\u00b1\u20094.4 weeks;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). BCVA remained stable, going from 0.41\u2009\u00b1\u20090.23 to 0.43\u2009\u00b1\u20090.24 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0112). The mean number of injections was 5.9\u2009\u00b1\u20091.9, with a mean follow-up duration of 51.4\u2009\u00b1\u200911.8 weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The switch to faricimab in a T&amp;E regimen significantly increased treatment intervals maintaining BCVA in patients with nAMD under other anti-VEGF treatments. No serious adverse events were reported. Longer follow-up is needed to confirm these results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-025-00776-0","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T17:20:58Z","timestamp":1764955258000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Faricimab treat-and-extend approach for neovascular age-related macular degeneration: insights from real-world clinical practice"],"prefix":"10.1186","volume":"12","author":[{"given":"Jorge","family":"Ruiz-Medrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia","family":"Pana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Garc\u00eda-Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Flores-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariluz","family":"Puertas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M\u00aa","family":"Ruiz-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"776_CR1","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.37765\/ajmc.2020.43436","volume":"26","author":"W Wong","year":"2020","unstructured":"Wong W. Managed care opportunities and approaches to select treatment for sight preservation. Am J Manag Care. 2020;26:S112\u20137.","journal-title":"Am J Manag Care"},{"key":"776_CR2","doi-asserted-by":"crossref","unstructured":"Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124(9):1296\u2013304.","DOI":"10.1016\/j.ophtha.2017.03.057"},{"key":"776_CR3","doi-asserted-by":"publisher","unstructured":"Zuber-Laskawiec K, Kubicka-Trzaska A, Karska-Basta I, Pociej-Marciak W, Romanowska-Dixon B. Non-responsiveness and tachyphylaxis to anti-vascular endothelial growth factor treatment in Naive patients with exudative age-related macular degeneration. J Physiol Pharmacol. 2019;70(5). https:\/\/doi.org\/10.26402\/jpp.2019.5.13.","DOI":"10.26402\/jpp.2019.5.13"},{"issue":"8","key":"776_CR4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1001\/jamaophthalmol.2018.2019","volume":"136","author":"L Lor\u00e9s-Motta","year":"2018","unstructured":"Lor\u00e9s-Motta L, Riaz M, Grunin M, Corominas J, van Asten F, Pauper M, et al. Association of genetic variants with response to anti-vascular endothelial growth factor therapy in age-related macular degeneration. JAMA Ophthalmol. 2018;136(8):875\u201384.","journal-title":"JAMA Ophthalmol"},{"issue":"15","key":"776_CR5","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41433-023-02505-z","volume":"37","author":"PE Stanga","year":"2023","unstructured":"Stanga PE, Valent\u00edn-Bravo FJ, Stanga SEF, Reinstein UI, Pastor-Idoate S, Downes SM. Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic. Eye (Lond). 2023;37(15):3282\u20139.","journal-title":"Eye (Lond)"},{"key":"776_CR6","doi-asserted-by":"publisher","unstructured":"Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016;8(11):1265\u20131288. Erratum in: EMBO Mol Med. 2019;11(5):e10666. https:\/\/doi.org\/10.15252\/emmm.201910666","DOI":"10.15252\/emmm.201910666"},{"issue":"5","key":"776_CR7","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41433-019-0670-1","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Faricimab: expanding horizon beyond VEGF. Eye (Lond). 2020;34(5):802\u20134.","journal-title":"Eye (Lond)"},{"issue":"10326","key":"776_CR8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. TENAYA and LUCERNE Investigators. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340.","journal-title":"Lancet"},{"key":"776_CR9","doi-asserted-by":"publisher","unstructured":"Mori R, Honda S, Gomi F, Tsujikawa A, Koizumi H, Ochi H, et al. TENAYA and LUCERNE Investigators. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial. Jpn J Ophthalmol. 2023;67(3):301\u2013310. Erratum in: Jpn J Ophthalmol. 2023;67(3):311. https:\/\/doi.org\/10.1007\/s10384-023-00996-7","DOI":"10.1007\/s10384-023-00996-7"},{"issue":"8","key":"776_CR10","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, et al. TENAYA and LUCERNE Investigators. TENAYA and LUCERNE: Two-Year results from the phase 3 neovascular Age-Related macular degeneration trials of faricimab with Treat-and-Extend dosing in year 2. Ophthalmology. 2024;131(8):914\u201326.","journal-title":"Ophthalmology"},{"key":"776_CR11","unstructured":"EURETINA education platform. 2020 EURETINA clinical survey outcomes. Available in: EURETINA-clinical-outcomes-2020.pdf Last accessed December 30, 2024."},{"issue":"2","key":"776_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10384-023-01040-4","volume":"68","author":"H Matsumoto","year":"2024","unstructured":"Matsumoto H, Hoshino J, Nakamura K, Akiyama H. One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-na\u00efve neovascular age-related macular degeneration. Jpn J Ophthalmol. 2024;68(2):83\u201390.","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"776_CR13","doi-asserted-by":"publisher","first-page":"21128","DOI":"10.1038\/s41598-023-48190-6","volume":"13","author":"R Tamiya","year":"2023","unstructured":"Tamiya R, Hata M, Tanaka A, Tsuchikawa M, Ueda-Arakawa N, Tamura H, et al. Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration. Sci Rep. 2023;13(1):21128. https:\/\/doi.org\/10.1038\/s41598-023-48190-6.","journal-title":"Sci Rep"},{"issue":"5","key":"776_CR14","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3390\/bioengineering11050478","volume":"11","author":"DR Muth","year":"2024","unstructured":"Muth DR, Fasler KF, Kvanta A, Rejdak M, Blaser F, Zweifel SA. Real-World weekly efficacy analysis of faricimab in patients with Age-Related macular degeneration. Bioeng (Basel). 2024;11(5):478. https:\/\/doi.org\/10.3390\/bioengineering11050478.","journal-title":"Bioeng (Basel)"},{"key":"776_CR15","doi-asserted-by":"publisher","unstructured":"Khodor A, Choi S, Nanda T, Caranfa JT, Ruiz-Lozano RE, Desai SH, et al. Visual and anatomic responses in patients with neovascular age-related macular degeneration and a suboptimal response to Anti-VEGF therapy switched to faricimab. J Vitreoretin Dis. 2024;24741264241271649. https:\/\/doi.org\/10.1177\/24741264241271649.","DOI":"10.1177\/24741264241271649"},{"key":"776_CR16","doi-asserted-by":"publisher","unstructured":"Ambati NR, Leone A, Brill D, Sisk RA. Real-World long-term outcomes of intravitreal faricimab in previously treated chronic neovascular age-related macular degeneration. Retina. 2024 Nov;11. https:\/\/doi.org\/10.1097\/IAE.0000000000004322.","DOI":"10.1097\/IAE.0000000000004322"},{"issue":"16","key":"776_CR17","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1038\/s41433-024-03218-7","volume":"38","author":"C Goodchild","year":"2024","unstructured":"Goodchild C, Bailey C, Soto Hernaez J, Ahmed E, Salvatore S. Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy. Eye (Lond). 2024;38(16):3059\u201364.","journal-title":"Eye (Lond)"},{"key":"776_CR18","doi-asserted-by":"publisher","unstructured":"Sim SY, Chalkiadaki E, Koutsocheras G, Nicholson L, Sivaprasad S, Patel PJ, et al. Moorfields medical retina injection service. Real-World 1-year outcomes of treatment-intensive neovascular age-related macular degeneration switched to faricimab. Ophthalmol Retina. 2024:S2468-6530(24)00355-5. https:\/\/doi.org\/10.1016\/j.oret.2024.07.020","DOI":"10.1016\/j.oret.2024.07.020"},{"issue":"1","key":"776_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00417-023-06222-x","volume":"262","author":"K Kataoka","year":"2024","unstructured":"Kataoka K, Itagaki K, Hashiya N, Wakugawa S, Tanaka K, Nakayama M, for Japan AMD Research Consortium (JARC), et al. Six-month outcomes of switching from Aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262(1):43\u201351.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"776_CR20","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.2147\/OPTH.S483563","volume":"18","author":"Y Qaseem","year":"2024","unstructured":"Qaseem Y, Hou KK, Pettenkofer MS. Outcomes after switching to faricimab for refractive macular edema in Treatment-Experienced eyes with neovascular Age-Related macular degeneration. Clin Ophthalmol. 2024;18:3097\u2013102.","journal-title":"Clin Ophthalmol"},{"issue":"11","key":"776_CR21","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1007\/s40123-024-01036-4","volume":"13","author":"G Cancian","year":"2024","unstructured":"Cancian G, Paris A, Agliati L, Rizzato A, Clerici M, Volpe G, et al. One-Year Real-World outcomes of intravitreal faricimab for previously treated neovascular Age-Related macular degeneration. Ophthalmol Ther. 2024;13(11):2985\u201397.","journal-title":"Ophthalmol Ther"},{"issue":"9","key":"776_CR22","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.oret.2025.03.015","volume":"9","author":"G Grimaldi","year":"2025","unstructured":"Grimaldi G, Ambresin A, Pfister IB, Schild C, Plasencia C, Hatz K, et al. One-Year outcomes after switching to faricimab in eyes with pretreated neovascular Age-Related macular degeneration: A Swiss retina research network report. Ophthalmol Retina. 2025;9(9):838\u201347.","journal-title":"Ophthalmol Retina"},{"key":"776_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.oret.2024.07.020","volume":"9","author":"SY Sim","year":"2025","unstructured":"Sim SY, Chalkiadaki E, Koutsocheras G, Nicholson L, Sivaprasad S, Praveen J, Patel, et al. Real-World 1-Year outcomes of Treatment-Intensive neovascular Age-Related macular degeneration switched to faricimab. Ophthalmol Retina. 2025;9:22\u201330.","journal-title":"Ophthalmol Retina"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00776-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00776-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00776-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:15:00Z","timestamp":1767856500000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-025-00776-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["776"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00776-0","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"2 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u201cAll procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards\u201d. Written informed consent to participate in the study has been obtained from all participants. The study was approved by the Ethics Committee of Puerta de Hierro University Hospital under protocol number 31\/25.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}